Mucosal targeting immunisation
CA 2337823 A1 · Owner: Aventis Pasteur · Inventors: Meignier, Bernard; Jourdier, Therese; Moste, Catherine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns the use of an immunogen specific of a pathogenic agent with a gateway in the buccal mucous membrane region for producing a vaccine , composition to be administered in the floor of the mouth in a human being so as to develop directly a local response in IgA antibodies and in B cells secreting IgA in the buccal mucous membrane saliva and ganglions draining , said mucous membrane. The invention also concerns a vaccine composition capable of being applied in the floor of the mouth in a human being to induce local and systemic immunity in IgA antibodies substantially consisting of a , material adhering or not to the buccal mucous membrane and containing an immunogen …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 28, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 28, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 28, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.